Brought to you by 
Noden gets worldwide license to Novartis hypertension drugs
11 Jul 2016
Executive Summary
Specialty pharmaceutical company Noden Pharma DAC licensed exclusive worldwide manufacturing, marketing, and sales rights to Novartis AG's hypertension drug Rasilez (aliskiren). The deal also includes Rasilez HCT, a fixed-dose tablet combination of aliskiren and hydrochlorothiazide (HCT).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Noden gets worldwide license to Novartis hypertension drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice